CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
Prasugrel (clinical formulation) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01430091
NCT01430091Phase 1Completed
CompareCT.gov

Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects

Eli Lilly and Company·interventional·Posted Sep 7, 2011·Updated Nov 6, 2012

In Brief

A Phase 1 clinical trial evaluating Prasugrel (clinical formulation) and Prasugrel (Orally Disintegrating Tablet [ODT]) for Sickle Cell Disease. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 7, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.8 years ago

Interventions

Prasugrel (clinical formulation)drug

Administered orally

Prasugrel (Orally Disintegrating Tablet [ODT])drug

Administered orally